Mutations in CBP and PCAF in Cancer Cell Lines
Author Information
Author(s): Özdağ H, Batley S J, Försti A, Iyer N G, Daigo Y, Boutell J, Arends M J, Ponder B A J, Kouzarides T, Caldas C
Primary Institution: University of Cambridge
Hypothesis
Are CBP and PCAF commonly inactivated in human epithelial cancers?
Conclusion
The study found inactivating mutations in CBP in cancer cell lines but not in primary tumors, suggesting a limited role for these genes in epithelial cancers.
Supporting Evidence
- Two truncating mutations in CBP were identified in cancer cell lines.
- No truncating mutations were found in 116 primary tumors.
- Missense alterations in PCAF were found in 5 out of 80 cancer cell lines.
Takeaway
The researchers looked for mutations in two genes related to cancer but found that these genes are not usually broken in real tumors, only in lab-grown cancer cells.
Methodology
The study screened the coding sequences and intron-exon boundaries of CBP and PCAF in various cancer cell lines and primary tumors.
Limitations
The absence of inactivating mutations in primary tumors limits the ability to establish a definitive role for CBP in human primary cancers.
Participant Demographics
The study included 59 primary breast tumors, 37 primary ovarian tumors, 20 colorectal tumors, and 63 cancer cell lines.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website